Key facts
- This page summarizes FIDELION DIAGNOSTICS PTE. LTD.'s Form 3 filing for BioNexus Gene Lab Corp (BGLC).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 07 Aug 2026, 16:28.
FIDELION DIAGNOSTICS PTE. LTD. - 28 Nov 2025 Form 3 Insider Report for BioNexus Gene Lab Corp (BGLC)
- Reporting relationship
- Greater than 5% holder
- Issuer ticker
- BGLC
- Reported as of
- 28 Nov 2025
- Net transaction value
- $0
- Reporting owner signature
- /s/ Ling Xiao
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
FIDELION DIAGNOSTICS PTE. LTD. filed Form 3 for BioNexus Gene Lab Corp (BGLC) on 07 Aug 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002104953
Primary reporting owner
FIDELION DIAGNOSTICS PTE. LTD.
- Relationship
- Greater than 5% holder
- Address
- 10 ANSON ROAD, #13-09, INTERNATIONAL PLAZA, SINGAPORE, SINGAPORE
- Signature
- /s/ Ling Xiao
- Signature date
- 04 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BGLC
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 392,329
- Date
- 28 Nov 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.